Navigation Links
Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
Date:7/9/2013

PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Signum Dermalogix, Inc. ("Dermalogix") a private biopharmaceutical company focused on developing new and innovative dermatological products and services announced that its Investigational New Drug (IND) Application to evaluate SIG990 in rosacea has been cleared by the U.S. Food and Drug Administration (FDA).

SIG990 is a safe topical treatment that addresses both erythema and inflammatory lesions and thus would be a significant and potentially better therapeutic option for rosacea patients then what is currently on the market. SIG990 is an isoprenylcysteine (IPC) analog that modulates toll-like receptor (TLR) and G-protein signaling demonstrating promising results in several in vitro cell based assays and efficacy in in vivo topical inflammatory animal models.

Instrumental in the pre-clinical development of SIG990 was funding from the National Institute of Allergy and Infectious Diseases (NIAID) via an SBIR grant. Dr. Eduardo Perez, VP of R&D and Business Development stated, "We thank NIAID for their support of this program. We would not have been able to perform the critical safety, pharmacology and manufacturing required without this grant support."

As a new chemical entity, SIG990 recently had composition of matter IP awarded (US Patent Application No. 12/566,839). Maxwell Stock, CEO of Dermalogix, commented, "We continue to make significant progress and are well-positioned to advance the development of our IPC compounds in dermatology. I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects."

About Signum Dermalogix
Signum Dermalogix, is a dermatological focused company, developing novel cosmetic ingredients and drug compounds. Dermalogix also provides dermatology testing, custom assay development and analytical services. For more information please visit: www.signumdermalogix.com


'/>"/>
SOURCE Signum Dermalogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
9. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
10. Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
(Date:5/10/2017)... 2017 Radiology has become the number one ... also spiraled to the number one ranking as a ... ever before as the most complete and reliable method ... lower back pain an MRI may confirm a suspected ... resulting in entirely different treatment protocols.  In these circumstances, ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for ... to sell luxury homes anywhere on the planet. The luxury home market is alive ... to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you ...
(Date:5/24/2017)... Birmingham, Clarkston, Lake Orion, Michigan (PRWEB) , ... ... ... Endometriosis is a disease affecting the female reproductive tract in which ... itself on the pelvic structures causing inflammation and pain. Patients experiencing painful ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, ... solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides ... the datacenter to the cloud to the edge. Through the new partnership, customers ...
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... ... May 24, 2017 , ... The CFOs included ... and health systems in the nation and help their organizations navigate the challenges ... and been instrumental in developing successful hospital and health system strategy. , Becker's ...
Breaking Medicine News(10 mins):